重磅!2017(第三届)下一代CAR&TCR-T研讨会 即将召开

2017-09-29 MedSci MedSci原创

2017年将可能成为CAR-T技术的标志性元年------诺华的CTL-019在今年3月获得了优先审评,用于治疗儿科及成人的复发或难治性B细胞型淋巴细胞白血病。今年4月,CTL-019又获得了FDA授予的突破性药物资格认定,用于治疗复发或难治性弥漫性大B细胞淋巴瘤。今年CTL-019很有可能获FDA批准上市,成为全球首个获批的CAR-T疗法!然而,CAR-T免疫细胞治疗在国内的发展并非一帆风顺。“



2017年将可能成为CAR-T技术的标志性元年------诺华的CTL-019在今年3月获得了优先审评,用于治疗儿科及成人的复发或难治性B细胞型淋巴细胞白血病。今年4月,CTL-019又获得了FDA授予的突破性药物资格认定,用于治疗复发或难治性弥漫性大B细胞淋巴瘤。今年CTL-019很有可能获FDA批准上市,成为全球首个获批的CAR-T疗法!
然而,CAR-T免疫细胞治疗在国内的发展并非一帆风顺。“魏则西事件”之后国家取消了免疫细胞治疗等第三类医疗技术的临床应用准入审批,意味着这类疗法目前只能开展临床研究。
为此生物谷举办“2017下一代CAR与TCR-T研讨会”, 邀请国内外知名的专家,学者,临床医生座谈,旨在促进医学界与科研机构的合作,探讨细胞治疗技术的安全性与有效性,推动CAR-T与TCR-T技术的临床应用及规范化治疗。

一、嘉宾





二、会议议题

基础研究
CAR的设计与安全性
肿瘤微环境与T 细胞持久性 (T cell persistence)
T 细胞归巢与实体瘤治疗
肿瘤突变负荷TMB与肿瘤新抗原产生
基于PDX模型的CAR-T临床前评价
人工智能AI 辅助肿瘤免疫治疗

技术进展-T细胞疗法升级改造
双肿瘤抗原识别CAR-T 
通用型CAR-T 
高亲和力高特异性的TCR
基因编辑技术改造的CAR-T
具有安全开关的CAR-T
非病毒载体的睡美人(sleeping beauty)技术

临床研究-血液病与实体瘤
靶向GPC3的CAR-T治疗肝癌
CAR-T治疗EphA2 阳性的复发转移的恶性胶质瘤 
针对HER2阳性的肿瘤CAR-T治疗
CAR-T序贯治疗弥漫性大 B 细胞淋巴瘤
CAR-T的输注方式与临床效果评价
免疫检查点抑制剂与CAR-T联用

T细胞治疗商业化
CAR-T 的商业化模式:on-the-shelf or off-the shelf
工程化的T细胞制备 
T细胞治疗的质量控制
T 细胞产品的监管与上市
T细胞治疗的商业保险问题
专利与知识产权保护

三、注册收费


四、联系方式

参会和媒体合作:
  朱赛博
 E-mail: saibo.zhu@medsci.cn
 Mt: 15021269895

赞助和大会咨询:
  陈颖杰 Andrew Chen
 E-mail: yingjie.chen@bioon.com
 Mt: 13661419496
  谢建胜
 E-mail: jiansheng.xie@bioon.com
 Mt: 18360734019(微信同号) 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994777, encodeId=7fce1994e775c, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jul 28 19:06:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510797, encodeId=fb931510e97f6, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17211, encryptionId=cfc41e2118a, topicName=TCR-T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0210252514, createdName=wenzhiren, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518942, encodeId=1950151894278, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17209, encryptionId=c8bb1e20902, topicName=TCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6b511213226, createdName=Boyinsh, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549190, encodeId=089f154919039, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248802, encodeId=2386248802da, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:26 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2018-07-28 kcb069
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994777, encodeId=7fce1994e775c, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jul 28 19:06:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510797, encodeId=fb931510e97f6, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17211, encryptionId=cfc41e2118a, topicName=TCR-T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0210252514, createdName=wenzhiren, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518942, encodeId=1950151894278, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17209, encryptionId=c8bb1e20902, topicName=TCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6b511213226, createdName=Boyinsh, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549190, encodeId=089f154919039, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248802, encodeId=2386248802da, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:26 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-10-01 wenzhiren
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994777, encodeId=7fce1994e775c, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jul 28 19:06:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510797, encodeId=fb931510e97f6, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17211, encryptionId=cfc41e2118a, topicName=TCR-T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0210252514, createdName=wenzhiren, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518942, encodeId=1950151894278, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17209, encryptionId=c8bb1e20902, topicName=TCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6b511213226, createdName=Boyinsh, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549190, encodeId=089f154919039, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248802, encodeId=2386248802da, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:26 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-10-01 Boyinsh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1994777, encodeId=7fce1994e775c, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jul 28 19:06:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510797, encodeId=fb931510e97f6, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17211, encryptionId=cfc41e2118a, topicName=TCR-T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0210252514, createdName=wenzhiren, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518942, encodeId=1950151894278, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17209, encryptionId=c8bb1e20902, topicName=TCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6b511213226, createdName=Boyinsh, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549190, encodeId=089f154919039, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248802, encodeId=2386248802da, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:26 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-10-01 xxxx1054
  5. [GetPortalCommentsPageByObjectIdResponse(id=1994777, encodeId=7fce1994e775c, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jul 28 19:06:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510797, encodeId=fb931510e97f6, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17211, encryptionId=cfc41e2118a, topicName=TCR-T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0210252514, createdName=wenzhiren, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518942, encodeId=1950151894278, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17209, encryptionId=c8bb1e20902, topicName=TCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6b511213226, createdName=Boyinsh, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549190, encodeId=089f154919039, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 04:06:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248802, encodeId=2386248802da, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:26 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 Y—xianghai

    学习了新知识

    0

相关资讯

CLIN CANCER RES:CART19治疗难治/复发急性淋巴细胞白血病

复发/难治急性淋巴细胞白血病(R/R ALL)患者预后较差。CART19具有抗白血病作用。但是中国患者的系统化试验数据尚缺乏。CLIN CANCER RES近期发表了一篇文章,报道中国CART19治疗急性淋巴细胞白血病的试验结果。

STM:cART治疗HIV/HCV共感染患者有效

根据辛辛那提大学(UC)研究人员带领的一项最新研究报道,用一种抗逆转录病毒药物疗法治疗感染丙型肝炎病毒(HCV)的HIV患者,不仅能解决HIV,还能减少HCV复制。相关研究结果发表在2014年7月23日的《科学转化医学》(Science Translational Medicine)杂志。 UC医学院消化疾病部门主任和医学教授Kenneth Sherman博士指出,

几种常见细胞治疗肿瘤技术:CART和NK细胞技术,其中taNK闪耀前景

免疫疗法是利用免疫系统来治疗疾病的一种概念:包括基于T细胞、B细胞及自然杀伤细胞(NK)等免疫细胞疗法。目前在CAR-T免疫疗法领域,除诺华及Juno外,其他跟进者包括Kite、基因治疗先驱蓝鸟生物(Bluebird bio)、生物技术巨头新基(Celgene),这些公司的细胞治疗技术皆是以T细胞为核心。一、CAR-T细胞CAR-T,全称是Chimeric Antigen Receptor T

CANCER RES:抗4-1BB联合CART可以增强肿瘤治疗效果

肿瘤的CART治疗在血液肿瘤中成功率较高,但是对于实体肿瘤,由于肿瘤微环境对免疫细胞的抑制功能,CART疗法能取得的成果有限。使用α-4-1BB抗体激活4-1BB(CD137)可以为T细胞分化提供共刺激信号,增强T细胞功能。